ClinicalTrials.gg
Active, not recruitingNCT06643481ASTRALSUpdated Jul 7, 2026

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2 interventional study of VHB937 and Placebo in Amyotrophic Lateral Sclerosis (ALS), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 74 sites in 17 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
32nd of 307
251 · median 33
Started
2024
with 19 others
Phase 2
89 of 440
8 open now
Primary completion
2026-06
later than 18 of 128 live
Registered
371st of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 32nd largest by enrollment of the 307 interventional ones that give a count, is one of 20 that started in 2024, is one of 89 in phase 2, reaches primary completion later than 18 of the 128 other live ones, and was the 371st registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).

Read the detailed description

The main questions this trial aims to answer in comparing VHB937 to placebo are:

  • How long will participants live without needing permanent help from a machine to breathe after starting the trial treatment?
  • What is the change in the participant's ability to perform daily activities? This will be measured using a questionnaire called the amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R).
  • What adverse events are reported during this trial? An adverse event is any sign or symptom that participants have during a trial. Adverse events may or may not be caused by treatments in the trial. The trial doctors will check participants' ALS and general health throughout the trial.
03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis
  • ALS
  • monoclonal antibody
  • motor neuron disease
  • MND
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • are 18 years of age or older
  • male or female, if of , strict required
  • have ALS confirmed by the trial doctors using different tests.
  • have mild symptoms of ALS as measured by the ALSFRS-R questionnaire (total score >=30).
  • have had symptoms of ALS (weakness) within 24 months of taking part in this trial.
  • have not received treatment for ALS or are currently on a stable dose of an approved treatment for ALS.
  • have the ability to slowly exhale a volume of air at least 60% of what is expected for the participant's sex, height and age.

Exclusion criteria

Exclusion Criteria:

  • Use of other drugs within 5 half-lives of screening, or within 30 days (e.g., small molecules) / or until the expected pharmacodynamic effect has returned to baseline (e.g., biologics), whichever is longer; or longer if required by local regulations.
  • Women of , defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of while taking study treatment and for 24 weeks after stopping study medication.
  • History or current diagnosis of cardiac conditions or abnormalities indicating significant risk of safety for participants in the study.
  • Clinical evidence of liver or renal disease/injury.
  • Laboratory evidence of hematological abnormalities
  • Presence of unstable psychiatric disease, cognitive impairment, neurological disease other than ALS, dementia or substance abuse that would impair ability of the participant to provide , in the investigator's opinion.
  • Participants that reported 'yes' on any suicidal ideation section except for the "Non-Suicidal Self-Injurious Behavior" in the past 2 years as per C-SSRS.
  • Presence of cancer, , Hep B, Hep C, tuberculosis, uncontrolled diabetes
  • History of active severe respiratory disease, including , interstitial lung disease or pulmonary fibrosis.
  • Taking any prohibited medications
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Arm 1

    I.V. infusions

    Biological: VHB937

  • Placebo comparator
    Arm 2

    I.V. infusions

    Other: Placebo

Interventions

  • BiologicalVHB937

    VHB937 solution for infusion

  • OtherPlacebo

    Solution for infusion

06

What researchers measure

Primary outcomes

  1. The composite of PAV-free survival and change in ALSFRS-R. Analysis method: Combined Assessment of Function and Survival (CAFS)

    To compare the efficacy of VHB937 vs. placebo on a composite of permanent assisted ventilation (PAV) free survival and function in DB epoch

    Time frame: Baseline to DB Week 40

Secondary outcomes

  1. ALS Functional Rating Scale Revised (ALSFRS-R) total score

    To assess the efficacy of VHB937 on functional decline in DB and OLE epochs.

    Time frame: Baseline to DB Week 40 or until death or PAV (whichever occurs first) and Baseline to OLE Week 100 or until death or PAV (whichever occurs first

  2. Slow Vital Capacity (SVC) (% of predicted normal value)

    To assess the efficacy of VHB937 in delaying decline in respiratory function in DB and OLE epochs.

    Time frame: Baseline to DB Week 40 or until death or PAV (whichever occurs first) and Baseline to OLE Week 100 or until death or PAV (whichever occurs first)

  3. Ratio to baseline in Neurofilament Light (NfL) concentration in serum

    To assess the effect of VHB937 on a biomarker of neurodegeneration in DB and OLE epochs.

    Time frame: DB up to Week 40; DB and OLE up to Week 100]

  4. Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    To assess the safety and tolerability of VHB937 in DB and OLE epochs.

    Time frame: Baseline to end of study

  5. Time to death and Time to event (death or PAV, whichever comes first).

    To assess the efficacy of VHB937 vs. placebo on survival endpoints in DB epoch.

    Time frame: Baseline to DB Week 40

  6. Time to death and Time to event (death or PAV, whichever comes first) - endpoints referring to treatment policy estimand

    To assess the efficacy of early vs. delayed VHB937 administration on survival endpoints (DB VHB937 followed by OLE VHB937 vs. DB placebo followed by OLE VHB937)

    Time frame: Baseline to OLE Week 100, and Baseline to end of study

  7. Patient Global Impression of change in functional ability and ALS symptom severity (PGI-C)

    To assess change in ALS condition in DB and OLE epochs.

    Time frame: DB up to Week 40; DB and OLE up to Week 100

  8. Change in QoL from baseline as measured with Amyotrophic Lateral Sclerosis Assessment Questionnaire -5 (ALSAQ-5)

    To assess Quality of Life (QoL) with VHB937 in DB and OLE epochs.

    Time frame: DB up to Week 40; DB and OLE up to Week 100

  9. Change in Clinician Global Impression of change in functional ability and ALS symptom severity (CGI-C)

    To assess change in ALS condition in DB and OLE epochs.

    Time frame: DB up to Week 40; DB and OLE up to Week 100

  10. Change in QoL from baseline as measured with EuroQoL 5 Dimension 5 Level (EQ-5D-5L)

    To assess Quality of Life (QoL) with VHB937 in DB and OLE epochs.

    Time frame: DB up to Week 40; DB and OLE up to Week 100

  11. Change in QoL from baseline as measured with 12-item Short form health survey (SF-12)

    To assess Quality of Life (QoL) with VHB937 in DB and OLE epochs.

    Time frame: DB up to Week 40; DB and OLE up to Week 100

  12. Pharmacokinetics (PK) of VHB937-CMAX

    CMAX - The maximum concentration of VHB937 in serum

    Time frame: Day 1 to end of study

  13. Pharmacokinetics (PK) of VHB937-TMAX

    TMAX - The time to reach the maximum concentration of VHB937 in serum

    Time frame: Day 1 to end of study

  14. Pharmacokinetics (PK) of VHB937-CTROUGH

    CTROUGH - Minimum observed concentration of VHB937 in serum

    Time frame: Day 1 to end of study

  15. To assess immunogenicity (IG) of VHB937

    To assess immunogenicity of Anti-VHB937 antibodies in serum

    Time frame: Day 1 up to end of study

  16. Cerebralspinal Spinal Fluid Pharmacokinetics (PK) of VHB937-CMAX

    CMAX - The maximum concentration of VHB937 in CSF

    Time frame: Screening to Week 12

  17. Cerebralspinal Spinal Fluid Pharmacokinetics (PK) of VHB937-TMAX

    TMAX - The time to reach the maximum concentration of VHB937 in CSF

    Time frame: Screening to Week 12

  18. Cerebralspinal Spinal Fluid Pharmacokinetics (PK) of VHB937-CTROUGH

    CTROUGH - Minimum observed concentration of VHB937 in CSF

    Time frame: Screening to Week 12

07

Study locations

74 sites
  • University of California San Diego
    La Jolla, California 92037, United States
  • Loma Linda University Health
    Loma Linda, California 92354, United States
  • Keck Medical Center USC
    Los Angeles, California 90033, United States
  • UC San Francisco Medical Center
    San Francisco, California 94143-0348, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Orlando Health Clinical Trials
    Orlando, Florida 32806, United States
  • Emory University School of Medicine
    Atlanta, Georgia 30322, United States
  • University Of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Lange Neurology PC
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Atrium Health
    Charlotte, North Carolina 28207, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • Univ of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • Temple University
    Philadelphia, Pennsylvania 19140, United States
  • AMR Knoxville
    Knoxville, Tennessee 37920, United States
  • Austin Neuromuscular Center
    Austin, Texas 78759, United States
  • Nerve and Muscle Center of Texas
    Houston, Texas 77030, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • Novartis Investigative Site
    North Ryde, New South Wales 2109, Australia
  • Novartis Investigative Site
    Herston, Queensland 4029, Australia
  • Novartis Investigative Site
    Caulfield South, Victoria 3162, Australia
  • Novartis Investigative Site
    Southport, 4215, Australia
  • Novartis Investigative Site
    Leuven, Vlaams Brabant 3000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Calgary, Alberta T2N 4N1, Canada
  • Novartis Investigative Site
    Montreal, Quebec H4A 3T2, Canada
  • Novartis Investigative Site
    Beijing, 100191, China
  • Novartis Investigative Site
    Aalborg, 9000, Denmark
  • Novartis Investigative Site
    Kobenhavn N V, 2400, Denmark
  • Novartis Investigative Site
    Bron, 69677, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Nice, 06001, France
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Tours, 37044, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68167, Germany
  • Novartis Investigative Site
    Munich, Bavaria 81675, Germany
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
  • Novartis Investigative Site
    Rostock, Mecklenburg-Vorpommern 18057, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Hanover, 30559, Germany
  • Novartis Investigative Site
    Lübeck, 23538, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Dublin, DUBLIN 9, Ireland
  • Novartis Investigative Site
    Milan, MI 20138, Italy
  • Novartis Investigative Site
    Modena, MO 41126, Italy
  • Novartis Investigative Site
    Pisa, PI 56126, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
  • Novartis Investigative Site
    Krakow, Poland 31 531, Poland
  • Novartis Investigative Site
    Bydgoszcz, 85-163, Poland
  • Novartis Investigative Site
    Krakow, 30-721, Poland
  • Novartis Investigative Site
    Warsaw, 01-684, Poland
  • Novartis Investigative Site
    Warsaw, 02-473, Poland
  • Novartis Investigative Site
    Yangsan, Gyeongsangnam-do 50612, South Korea
  • Novartis Investigative Site
    Seoul, 04763, South Korea
  • Novartis Investigative Site
    Seoul, 05505, South Korea
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Valencia, 46026, Spain
  • Novartis Investigative Site
    Malmö, 214 28, Sweden
  • Novartis Investigative Site
    Stockholm, 113 61, Sweden
  • Novartis Investigative Site
    Umeå, SE-90185, Sweden
  • Novartis Investigative Site
    Basel, 4031, Switzerland
  • Novartis Investigative Site
    Sankt Gallen, 9007, Switzerland
  • Novartis Investigative Site
    Sheffield, South Yorkshire S10 2JF, United Kingdom
  • Novartis Investigative Site
    Farnborough, BR6 8ND, United Kingdom
  • Novartis Investigative Site
    London, SW17 0QT, United Kingdom
  • Novartis Investigative Site
    London, WC1N 3BG, United Kingdom
  • Novartis Investigative Site
    Stoke-on-Trent, ST4 6QG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jun 2026, 20 months.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 20 months is close to that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 16, 2024
StartActual
Oct 17, 2024
Primary completionActual
Jun 23, 2026
CompletionEst.
Jul 10, 2028
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06643481
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Oct 17, 2024
Primary completion
Jun 23, 2026
Completion
Jul 10, 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion